FHIR Release 3 (STU) 4

This page is part of the FHIR Specification (v3.0.2: (v4.0.1: R4 - Mixed Normative and STU 3). ) in it's permanent home (it will always be available at this URL). The current version which supercedes this version is 5.0.0 . For a full list of available versions, see the Directory of published versions . Page versions: R4 R3 R4 R3

4.3.2.1070 4.4.2.1070 HL7 v3 Value Set substanceAdminSubstitution

Vocabulary Work Group   Maturity Level : N/A External Use Context : Any

This value set (http://hl7.org/fhir/ValueSet/v3-substanceAdminSubstitution) (http://terminology.hl7.org/ValueSet/v3-substanceAdminSubstitution) is defined as part of HL7 v3.

Summary

Defining URL: http://hl7.org/fhir/ValueSet/v3-substanceAdminSubstitution http://terminology.hl7.org/ValueSet/v3-substanceAdminSubstitution
Version: 2018-08-12
Name: v3.substanceAdminSubstitution
Title: v3 Code System substanceAdminSubstitution
Definition:

Identifies what sort of change is permitted or has occurred between the therapy that was ordered and the therapy that was/will be provided.

OID: (for OID based terminology systems)
Source Resource XML / JSON

This value set is used in the following places:

4.3.2.1070.1 4.4.2.1070.1 Content Logical Definition

This value set includes codes from the following code systems:

 

4.3.2.1070.2 4.4.2.1070.2 Expansion

This expansion generated 19 Apr 2017 01 Nov 2019

This value set contains 9 concepts

Expansion based on http://hl7.org/fhir/v3/substanceAdminSubstitution http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution version 2016-11-11 2018-08-12

All codes from system http://hl7.org/fhir/v3/substanceAdminSubstitution http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution

Lvl Code Display Definition
0 _ActSubstanceAdminSubstitutionCode ActSubstanceAdminSubstitutionCode Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects.
1    E equivalent Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.
2      EC equivalent composition Description: Substitution occurred or is permitted with another product that is a: pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples: Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril
3        BC brand composition Description: Substitution occurred or is permitted between equivalent Brands but not Generics Examples: Zestril for Prinivil Coumadin for Jantoven
3        G generic composition Description: Substitution occurred or is permitted between equivalent Generics but not Brands Examples: Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
2      TE therapeutic alternative Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. Examples: ranitidine for Tagamet
3        TB therapeutic brand Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics > Examples: Zantac for Tagamet
3        TG therapeutic generic Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands > Examples: Ranitidine for cimetidine
1    F formulary Description: This substitution was performed or is permitted based on formulary guidelines.
1    N none No substitution occurred or is permitted.